Aromatic nitrogenous six-membered ring compounds

专利摘要:
The present invention relates to an aromatic nitrogen-containing 6-membered cyclic compound of the general formula (I), or a pharmaceutically acceptable salt thereof, which exhibits excellent selective PDE V inhibitory action and is useful as a preventive or remedy for penile erectile dysfunction or the like: (I) Wherein A is an optionally substituted nitrogen-containing heterocyclic group; R 1 is optionally substituted lower alkyl, -NH-QR 3 wherein R 3 is an optionally substituted nitrogen containing heterocyclic group and Q is lower alkylene or a single bond or -NH-R 4 ( Wherein R < 4 > is optionally substituted cycloalkyl; R < 2 > is optionally substituted aryl; One of Y and Z is-CH-, and the other is -N.
公开号:KR20020047170A
申请号:KR1020027003536
申请日:2000-09-13
公开日:2002-06-21
发明作者:야마다고이찌로；마쯔끼겐지；오모리겐지；기까와고헤이
申请人:찌바따 이찌로, 다나까 도시오；다나베 세이야꾸 가부시키가이샤；
IPC主号:

专利说明:

[0001] AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS [0002]
[2] In general, the intracellular second messenger, cGMP, is degraded and inactivated by phosphodiesterase, which is widely distributed in many cell types and tissues of the body, and when the PDE activity is inactivated, , Resulting in various pharmacological actions, for example relaxation of vascular smooth muscle, relaxation of bronchial smooth muscle, and platelet aggregation control.
[3] In addition, the cGMP-specific PDE inhibitor (i. E., PDE V inhibitor) is useful for the treatment of diseases caused by dysfunction of cGMP system signal transduction, and the diseases are hypertension, angina pectoris, myocardial infarction, chronic or acute heart failure, [See PCT Patent Publication WO 96/05176 and the like], and prostate enlargement [Australian Patent Publication No. 9955977]. In addition, PDE V inhibitors have been used to treat female sexual dysfunction [Vemulapalli et al., Life Sciences, 67 : 23-29 (2000)], diabetic gastroparesis [Watkins et al., J. Clin. Invest. 106 : 373-384 (2000)], achalasia (Bortolotti et al., Gastroenterology; 118 : 253-257 (2000)], diarrhea [Mule et al., Br. J. Pharmacol., 127 : 514-520 (1999)], constipation [Bakre et al., J. Cell. Biochem. 77 : 159-167 (2000)], asthma [Turner et al., Br. J. Pharmacol., 111 : 1198-1204 (1994)].
[4] In addition, the present inventors have also found that 1- [4-ethoxy-3- (6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H- pyrazolo [4,3- 5-yl) phenylsulfonyl] -4-methylpiperazine [generic name: Sildenafil] has been reported to be useful for the treatment of diseases such as penile erectile dysfunction (incompetence) (Boolell et al. 6, no. 15, p. 1819 (1996)], and the like, and the like) [Ballard et al., British Journal of Pharmacology, Proceeding Supplement, vol. 118, p.
[5] However, sildenafil has been shown to be effective in the treatment of headache, facial flushing, gastrointestinal tract disorders, rhinitis, color vision disorders, erectile dysfunction (Irwin et al., The New England Journal of Medicine, 338, 10, No. 2, p. 69-73 (1998); and [Goldenberg, Clinical Therapeutics, vol. 20, no. 6, p. 1033-1048 (1998)). ≪ / RTI >
[6] Also, in dog experiments, it has been reported that sildenafil affects the photoreaction of retinal tissue and is correlated with its PDE VI inhibition (Morales et al., International Journal of Impotence Research, vol. 10, no. 2, p. 69-73 (1998)], while it has been reported that PDE Ⅵ of the retina plays an important role in the perception of light [Morales et al., International Journal of Impotence Research, vol. 10, no. 2, p. 69-73 (1998); Estrade et al., European Journal of Pharmacology, vol. 352, p. 157-163 (1998)).
[1] The present invention relates to novel aromatic nitrogen-containing 6-ring cyclic compounds which exhibit cGMP-specific phosphodiesterase (PDE) inhibitory action (PDE V inhibiting action) and which are useful as medicaments and a process for the preparation thereof.
[7] It is an object of the present invention to provide a novel aromatic nitrogen-containing 6-membered cyclic compound useful as a therapeutic agent for preventing or treating erectile dysfunction of the penis which exhibits excellent phosphodiesterase V (PDE V) inhibitory action and has a low side effect . Another object of the present invention is to provide a process for producing the novel aromatic nitrogen-containing 6-ring compound.
[8] The present invention relates to an aromatic nitrogen-containing 6-membered cyclic compound of formula (I), or a pharmaceutically acceptable salt thereof, and a process for preparing the same.
[9]
[10] Wherein ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R ¹ is a substituted or unsubstituted lower alkyl group, a group of the formula: -NH-QR ³ (wherein R ³ is a substituted or unsubstituted nitrogen containing heterocyclic group, Q is a lower alkylene group or a single bond) -R ⁴ (wherein R ⁴ is a substituted or unsubstituted cycloalkyl group); R ² is a substituted or unsubstituted aryl group; One of Y and Z is a group of the formula CH3 and the other is a group of the formula:
[11] In the compound (I) of the present invention, the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen containing heterocyclic group" to the ring A is a 5- to 10-membered monocyclic or bicyclic nitrogen-containing heterocyclic group, A 5- or 6-membered nitrogen containing complex monocyclic group and / or an 8- to 10-membered nitrogen containing heterocyclic group, most particularly a pyrrolidinyl group, a piperazinyl group, a piperidyl group, a morpholino group and the like A 5- or 6-membered aromatic nitrogen-containing complex monocyclic group, a 5- or 6-membered aromatic nitrogen-containing complex monocyclic group, an imidazolyl group, a pyrrolyl group and the like, and a 6,7-dihydro- Pyrrolo [3,4-b] pyridin-6-yl group, 5,6,7,8-tetrahydroimidazo [1,2- a] pyrazin-7-yl group, , 8-tetrahydro-1,7-naphthyridin-7-yl group, 1,2,3,4-tetrahydro-2-isoquinolinyl group, 1H-2,3,4,5,6,7 -Hexahydro-pyrazolo [4,3-c] pyridin-5-yl group, 4,5,6,7- Yl group, 5,6,7,8-tetrahydropyrido [4,3-d] pyrimidin-6-yl group, 4,5,6-tetrahydropyrido [ , 7-tetrahydro-3H-imidazo [4,5-c] pyridin-3-yl group and the like.
[12] The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ may be a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10-membered nitrogen containing heterocyclic group, A 5- or 6-membered non-aromatic nitrogen-containing complex monocyclic group such as a morpholinyl group, a piperazinyl group, a piperidyl group, a thiadiazolyl group, a dihydropyrimidinyl group and a dihydropyrazolyl group, A 5- or 6-membered aromatic nitrogen-containing complex monocyclic group such as a pyridyl group, a pyridyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group and a pyrazinyl group, and A benzothiazolyl group, a quinolyl group, a dihydrobenzoxazolyl group, and other heterocyclic groups containing 8 to 10-membered nitrogen.
[13] Examples of the substituent of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for the rings A and R ³ include (1) a lower alkyl group, (2) a hydroxy-substituted lower alkyl group, (3) a formyl group, (6) di- (lower alkyl) amino group, (7) hydroxy group, (8) lower alkoxy group, (9) lower alkoxycarbonyl group, (10) lower alkoxy substituted lower alkanoyl group (11) a lower alkanoyl group, (12) a cyano-substituted lower alkyl group, and (13) (i) a benzylamino group substituted by a halogen atom and a lower alkoxy group, and (ii) a cycloalkylcarbamoyl group substituted by a hydroxy group A substituted pyrimidinyl group and the like.
[14] The aryl group of the "substituted or unsubstituted aryl group" for R ² is, for example, a 5- to 10-membered monocyclic or bicyclic aromatic hydrocarbon group such as phenyl group, naphthyl group and the like.
[15] Examples of the substituent of the "substituted or unsubstituted aryl group" for R ² include a lower alkoxy group, a halogen atom, a cyano group, a nitro group, a hydroxy group, a lower alkyl group and the like.
[16] Examples of the substituent of the "substituted or unsubstituted lower alkyl group" for R ¹ and the "substituted or unsubstituted cycloalkyl group" for R ⁴ include a lower alkoxy group, a hydroxy group, a morpholinyl group, a lower alkylsulfonyl group (Lower alkyl) amino group, a pyrimidinyl-substituted lower alkylamino group, a pyridyl group, a pyridylamino group, a lower alkyl-substituted piperazinyl group, a pyrimidinyloxy group, etc. to be.
[17] In the present specification and claims, the "lower alkyl group" means a straight or branched chain alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl and the like. Means a straight or branched chain alkoxy group having 1 to 6 carbon atoms such as methoxy, ethoxy, propoxy, isopropyloxy, butyloxy, isobutyloxy, tert-butyloxy and the like .
[18] The term "cycloalkyl group" means a cycloalkyl having 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like. The "lower alkylene group" means a linear or branched alkylene group having 1 to 6 carbon atoms, such as methylene, ethylene, trimethylene, and the like.
[19] &Quot; Halogen atom " means a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
[20] Among the compounds (I) of the present invention, preferred compounds are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" to the ring A is a 5- or 6-membered nitrogen containing complex monocyclic group, (1) a lower alkyl group, (2) a hydroxy-substituted lower alkyl group, (3) a formyl group, (4) a nitrogen-containing heterocyclic group, (7) a lower alkoxycarbonyl group, and (8) a benzylamino group substituted by (i) a halogen atom and a lower alkoxy group, and (ii) a cycloalkylcarbamoyl group substituted by a hydroxy group, (Lower alkyl) amino group, a di (lower alkyl) phosphino group, a di- (lower alkyl) amino group or a pyrrolyl group substituted with a lower alkyl group; R ¹ is selected from the group consisting of a lower alkoxy group, a hydroxy group, a morpholinyl group, a lower alkylsulfonyl group, , Pyrimidinyl substituted lower alkylamino And the group, a pyridyl group, a pyridyl group and a lower alkyl-substituted piperazinyl group by a group selected from the group consisting of optionally substituted lower alkyl group as possible, the formula -NH-QR ³ group, or the formula -NH-R ⁴ in the group, R ³ Quot; substituted or unsubstituted nitrogen-containing heterocyclic group " for the nitrogen-containing heterocyclic group is a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10-membered nitrogen containing heterocyclic group, Unsubstituted nitrogen-containing heterocyclic group "is a group selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, an oxo group, an amino group, a di- (lower alkyl) amino group, a lower alkanoyl group and a cyano-substituted lower alkyl group selected and, R ⁴ is a hydroxy group, a lower alkoxy group and a pyrimidinyl group, and oxy a cycloalkyl group substituted by a group selected from the group consisting of, R ² is a lower alkoxy group, a halogen atom, a cyano group, a nitro Of a compound of formula Ⅰ a phenyl group substituted by a group selected from, the group consisting of a hydroxy group and a lower alkyl group.
[21] More preferably, the preferred compounds of the present invention are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen containing heterocyclic group" for ring A is a 5- or 6-membered nitrogen containing complex monocyclic group of the formula:
[22]
[23] Or a nitrogen-containing heterocyclic bicyclic group of the formula: wherein the 5- or 6-membered nitrogen containing complex monocyclic group is condensed with a 5- or 6-membered cyclic group,
[24]
[25] The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the formula:
[26]
[27] Or a compound of formula I, which is an aromatic nitrogen containing heterocyclic group of the formula:
[28] .
[29] Among the compounds (I) of the present invention, other preferred compounds are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group, a 10-membered bicyclic nitrogen-containing heterocyclic group, wherein the substituents of the "substituted or unsubstituted nitrogen-containing heterocyclic group" is selected from lower alkyl, hydroxy-lower alkyl group, a formyl group, and the group consisting of oxo groups substituted, R ¹ is a lower alkoxy group and a morpholinyl group optionally substituted by a group selected from the group consisting of a lower alkyl group as possible, the formula -NH-QR ³ is a group or a group of the formula -NH-R ^4, the containing "substituted or unsubstituted nitrogen of the R ³ heterocyclic Is a 5- or 6-membered nitrogen-containing complex monocyclic group optionally substituted by a lower alkyl group, and R < ⁴ > is a group selected from the group consisting of a hydroxyl group and a lower alkoxy group And R ² is a phenyl group substituted with a group selected from the group consisting of a lower alkoxy group, a halogen atom and a cyano group.
[30] More preferably, the preferred compounds of the present invention are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen containing heterocyclic group" for ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group of the formula:
[31]
[32] Or a nitrogen-containing heterocyclic bicyclic group of the formula: wherein the 5- or 6-membered non-aromatic nitrogen-containing complex monocyclic group is condensed with a 5- or 6-membered aromatic nitrogen-containing complex monocyclic group,
[33]
[34] The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the formula:
[35]
[36] Or a compound of formula (I), which is an aromatic nitrogen containing complex monocyclic group of the formula:
[37]
[38] More particularly, preferred compounds of the present invention are those wherein Ring A is a group of the formula:
[39]
[40] R ¹ is a lower alkyl group, a lower alkoxy-substituted lower alkyl group, a morpholinyl-substituted lower alkyl group, a group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , R ³ is a group of the formula:
[41]
[42] R ⁴ is
[43] The Lt; / RTI >
[44] R ² is
[45] The Lt; / RTI >
[46] Among the compounds (I) of the present invention, more preferred compounds are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" to the ring A is a 5- or 6-membered nitrogen containing complex monocyclic group, A nitrogen-containing heterocyclic group and the substituent of the "substituted or unsubstituted nitrogen-containing heterocyclic group" is a group selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, a formyl group and an oxo group, and R ¹ Is a lower alkoxy-substituted lower alkyl group, a group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , and the "substituted or unsubstituted nitrogen containing heterocyclic group" for R ³ is an optionally substituted a 5-or 6-membered nitrogen-containing heterocyclic single cyclic group, R ⁴ is a cycloalkyl group substituted with hydroxy, R ² is substituted by a group selected from a lower alkoxy group and a halogen atom, the group consisting of Fe Group, a compound of formula Ⅰ.
[47] More particularly, the more preferred compounds of the present invention are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen containing heterocyclic group" for ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group of the formula:
[48]
[49] Or a group of the formula:
[50]
[51] The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the formula:
[52]
[53] Is a compound of formula (I), which is an aromatic nitrogen-containing complex monocyclic group of the formula:
[54] .
[55] More particularly, more preferred compounds of the invention are those, wherein Ring A is a group of the formula:
[56]
[57] R ¹ is a lower alkoxy substituted lower alkyl group, a group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , R ³ is a group of the formula:
[58]
[59] R ⁴ is
[60] The Lt; / RTI >
[61] R ² is
[62] The Lt; / RTI >
[63] More preferred compounds of the present invention are those wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" to the ring A is a 5- or 6-membered nitrogen containing complex monocyclic group or 8 Wherein the substituent of the "substituted or unsubstituted nitrogen-containing heterocyclic group" is a hydroxy-substituted lower alkyl group, R ¹ is a group of the formula -NH-QR ³ , R ³ Quot; substituted or unsubstituted nitrogen containing heterocyclic group " is a 5- or 6-membered nitrogen-containing heterocyclic monocyclic group optionally substituted by a lower alkyl group, and R ² is a group selected from the group consisting of a lower alkoxy group and a halogen atom Lt; / RTI > is a substituted phenyl group.
[64] More particularly, a more preferred compound of the present invention is a compound wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group :
[65]
[66] Or a group of the formula:
[67]
[68] The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the following formula:
[69]
[70] Or a compound of formula (I) which is an aromatic nitrogen-containing complex monocyclic group of the formula:
[71] .
[72] More particularly, preferred compounds of the present invention are those wherein Ring A is a group of the formula:
[73]
[74] R ¹ is a group of the formula -NH-QR ³ , R ³ is a group of the formula:
[75]
[76] R ² is
[77] The Lt; / RTI >
[78] Among the compounds (I) of the present invention, the most preferred compounds are those of the formula (I) in which Y is a group of the formula --N- and Z is a group of the formula --CH--.
[79] Among the compounds (I) of the present invention, the pharmaceutically preferred compounds are those selected from the following group, or a pharmaceutically acceptable salt thereof.
[80] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
[81] 4- (3-cyano-4-methoxybenzylamino) -5- [N- ( 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
[82] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- Trans-4-methoxycyclohexyl) carbamoyl] pyrimidine;
[83] 4- (3-cyano-4-methoxybenzylamino) -5- [N- ( Trans-4-hydroxycyclohexyl) carbamoyl] pyrimidine;
[84] 4- (3-cyano-4-methoxybenzylamino) -5- [N- ( 2-morpholinoethyl) carbamoyl] pyrimidine;
[85] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (2-morpholinoethyl) carbazole Yl] pyrimidine;
[86] (2S) -2-hydroxymethyl-1-pyrrolidinyl] -4- (3-chloro-4-methoxybenzylamino) 2-morpholinyl] methyl] carbamoyl] pyrimidine;
[87] [(2S) -2-hydroxymethyl-1-pyrrolidinyl] -4- (3-chloro-4- methoxybenzylamino) 2-morpholinyl] methyl] carbamoyl] pyrimidine;
[88] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyrimidinylmethyl) Yl] pyrimidine;
[89] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4-hydroxycyclohexyl) carbazole Yl] pyrimidine;
[90] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4- hydroxycyclohexyl) carbamoyl] pyrimidine Midin;
[91] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- Trans-4-hydroxycyclohexyl) carbamoyl] pyrimidine;
[92] (3-chloro-4-methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) ) ≪ / RTI > carbamoyl] pyrimidine;
[93] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
[94] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-morpholinoethyl) carbamoyl] pyrimidine;
[95] 4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
[96] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) -5-acetylpyrimidine;
[97] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyridazinylmethyl) Yl] pyrimidine;
[98] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine;
[99] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyridylmethyl) carbamoyl ] Pyrimidine;
[100] (3-chloro-4-methoxybenzylamino) -5- [2-hydroxymethyl-1-pyrrolyl Dinyl] pyrazine;
[101] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2-morpholinoethyl) carbonyl] Midin;
[102] 4- (3-Chloro-4-methoxybenzylamino) -5- [N- [2-fluoro- (4-methyl-2-morpholinyl) methyl] carbamoyl] pyrimidine;
[103] (3-chloro-4-methoxybenzylamino) -5- [2-hydroxymethyl-1-pyrrolyl Dinyl] pyrazine;
[104] 2- [N- (2-pyrimidinylmethyl) carbamoyl] -3- (3-chloro-4- methoxybenzylamino) -5- (5,6,7,8-tetrahydroimidazo [ , 2-a] pyrazin-7-yl) pyrazine;
[105] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2- methoxyethyl) carbonyl] pyrimidine ;
[106] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[107] Among the compounds (I) of the present invention, the pharmaceutically preferred compounds are the compounds selected from the following group or pharmaceutically acceptable salts thereof.
[108] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
[109] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyrimidinylmethyl) Yl] pyrimidine;
[110] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4-hydroxycyclohexyl) carbazole Yl] pyrimidine;
[111] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4- hydroxycyclohexyl) carbamoyl] pyrimidine Midin;
[112] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
[113] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-morpholinoethyl) carbamoyl] pyrimidine;
[114] 4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
[115] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine;
[116] (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
[117] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2- methoxyethyl) carbonyl] pyrimidine ;
[118] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[119] Among the compounds (I) of the present invention, other pharmaceutically favorable compounds are the compounds selected from the following group or pharmaceutically acceptable salts thereof.
[120] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
[121] 4- (3-chloro-4-methoxybenzylamino) -5- [N- (2-morpholinoethyl) carbazole Yl] pyrimidine;
[122] 2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
[123] 4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
[124] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine
[125] (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
[126] 3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
[127] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[128] Among the compounds (I) of the present invention, particularly pharmaceutically preferable compounds are the compounds selected from the following group or pharmaceutically acceptable salts thereof.
[129] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl) -4- (3-chloro-4-methoxyphenyl) pyrimidine, or a pharmaceutically acceptable salt thereof, Benzylamino) -5- [N- (2-morpholinoethyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof; (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- Trimethyl-4-pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[130] When compound (I) of the present invention or a pharmaceutically acceptable salt thereof has an asymmetric carbon in ring A, R ¹ and / or R ² , it is present in the form of its optically active isomer due to its asymmetric carbon atom And the present invention also encompasses optical isomers and mixtures thereof.
[131] The compound (I) of the present invention or a pharmaceutically acceptable salt thereof has excellent selective PDE V inhibiting action but is substantially free from side effects such as color vision abnormality and thus can be used for prevention and treatment of penile erectile dysfunction .
[132] The compound (I) of the present invention can be used for pharmaceutical use in the form of a free form or a pharmaceutically acceptable salt thereof. The pharmaceutically acceptable salts of compounds (I) are those salts with inorganic acids such as hydrochlorides, sulfates, nitrates or hydrobromides, or with organic acids such as acetate, fumarate, oxalate, citrate, methanesulfonate, benzenesulfonate, tosylate or And salts with organic acids such as maleate.
[133] The present compound (I) or a salt thereof includes an intramolecular salt or an additive thereof, and a solvate thereof or a hydrate thereof
[134] The present compound (I) or a pharmaceutically acceptable salt thereof may be administered orally or parenterally and may be formulated into tablets, granules, microgranules, pills, capsules, powders, injections, inhalants, And may be formulated into conventional pharmaceutical preparations such as syrups, jellies, suppositories, ointments, elixirs, linings, lotions, drinks, nasal drops, percutaneous preparations, and oral disintegrating preparations in the mouth. The pharmaceutical preparations can be formulated in conventional manner together with pharmaceutically acceptable additives such as excipients, binders, wetting agents, disintegrants, extenders and the like.
[135] The dosage of the compound (I) of the present invention or a pharmaceutically acceptable salt thereof varies depending on the route of administration, the age, weight and condition of the patient. For example, when administered as an injection, it is typically in the range of about 0.001-100 mg / kg / day, preferably about 0.1-10 mg / kg / day. When administered as an oral preparation, it is typically in the range of about 0.1-200 mg / kg / day, preferably about 0.1-80 mg / kg / day.
[136] In addition, since the compound (I) of the present invention, or a pharmaceutically acceptable salt thereof, exhibits excellent selective PDE V inhibitory action, it is useful as a medicament for treating diseases caused by dysfunction of cGMP system signal transduction such as pulmonary hypertension, It may also be useful in the prevention or treatment of sexual dysfunction, hypertension, angina pectoris, myocardial infarction, chronic or acute heart failure, female sexual dysfunction, prostate hypertrophy, asthma, diarrhea, constipation and achalasia, and erectile dysfunction.
[137] BEST MODE FOR CARRYING OUT THE INVENTION [
[138] The compound (I) of the present invention can be prepared by the following method A to method F:
[139] Method A
[140] Among the compounds (I) of the present invention, the compound wherein R ¹ is of the formula -NH-QR ³ or -NH-R ⁴ , that is, the compound of the formula (I-a)
[141]
[142] (Wherein R ¹¹ is a group of the formula -NH-QR ³ or -NH-R ⁴ , and the other symbols are as defined above)
[143] Reacting a compound of formula (II): < EMI ID =
[144]
[145] (Wherein X ¹ is a halogen atom, R ⁵ is a protecting group of a carboxyl group, R ⁹ is a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aryl group, and the other symbols are as defined above)
[146]
[147] (Wherein the symbols are as defined above),
[148] The resulting compound of formula IV is oxidized to give:
[149]
[150] (Wherein the symbols are as defined above)
[151] To obtain a sulfonyl (or sulfinyl) compound of formula V:
[152]
[153] (Wherein n is 1 or 2 and the other symbols are as defined above)
[154] Reacting compound (V) with a compound of formula (VI)
[155]
[156] (Wherein the symbols are as defined above)
[157] To obtain a compound of formula VII:
[158]
[159] (Wherein the symbols are as defined above),
[160] Removal of the protecting group R < ⁵ > for the carboxyl group of compound (VII) yields the compound of formula VIII:
[161]
[162] (Wherein the symbols are as defined above),
[163] Can then be prepared by reacting compound (VIII) with a compound of formula IX-a:
[164] R ¹¹ -H
[165] (Wherein the symbols are as defined above).
[166] Compound (I-a) can also be halogenated to give a compound of formula (X): < EMI ID =
[167]
[168] (Wherein X ² is a halogen atom and the other symbols are as defined above)
[169] Subsequently, it can be prepared by reacting compound (X) with compound (IX-a).
[170] The compound (VII) can be produced by treating the dihalogeno compound of the formula (XI) with carbon dioxide,
[171]
[172] (Wherein X ³ and X ⁴ are halogen atoms and the other symbols are as defined above)
[173] Protecting the resulting carboxyl group of the compound of formula (XII)
[174]
[175] (Wherein the symbols are as defined above)
[176] To obtain a compound of formula (XIII): < EMI ID =
[177]
[178] (Wherein the symbols are as defined above),
[179] Reacting compound (XIII) with compound (III) to obtain a compound of formula XIV:
[180]
[181] (Wherein the symbols are as defined above),
[182] Followed by reacting compound (XIV) with compound (VI).
[183] In addition, the compound (XIV) can also be prepared by hydrolyzing the compound (V) and then halogenating the resulting compound of the formula (XV):
[184]
[185] (Wherein the symbols are as defined above).
[186] Method B
[187] Among the compounds (I) of the present invention, the compound of the formula (I) wherein R ¹ is a substituted or unsubstituted lower alkyl group, i.e. the compound of the formula (I-b)
[188]
[189] (Wherein R ¹² is a substituted or unsubstituted lower alkyl group and the other symbols are as defined above)
[190] Oxidation of a compound of formula XVI, obtained by reduction of compound (IV)
[191]
[192] (Wherein the symbols are as defined above)
[193] To obtain a compound of formula XVII:
[194]
[195] (Wherein the symbols are as defined above),
[196] Further oxidizing the compound (XVII) to give a compound of the formula XVIII:
[197]
[198] (Wherein the symbols are as defined above),
[199] Reacting compound (XVII) with compound (VI) to obtain a compound of formula (XIX): < EMI ID =
[200]
[201] (Wherein the symbols are as defined above),
[202] Reacting compound (XIX) with a metal salt of a compound of formula (IX-b)
[203] R ¹² -H
[204] (Wherein R < ¹² > is as defined above)
[205] To obtain a compound of formula XX: < EMI ID =
[206]
[207] (Wherein the symbols are as defined above),
[208] Subsequently, it can be prepared by oxidizing the compound (XX).
[209] In the compound (I) of the present invention, it is also possible that R ¹ is a lower alkoxy substituted ethyl group, a morpholino substituted ethyl group, a 4-lower alkylpiperazinyl group substituted ethyl group, a 3-pyridylamino substituted ethyl group, Pyridyl lower alkylamino group is a substituted ethyl group, a di-lower alkylaminoethyl group or a hydroxyethyl group, that is, a compound of the following formula I-c:
[210]
[211] (Wherein R ⁶ is a lower alkoxy group, a morpholino group, a 4-lower alkylpiperazinyl group, a 3-pyridylamino group, a 2-pyrimidyl lower alkylamino group, a di-lower alkylamino group or a hydroxy group, Lt; / RTI > as defined above)
[212] Compound (XIX) is reacted with a Grignard compound of formula (XXI)
[213] CH ₂ = CHMgBr
[214] To obtain a compound of formula < RTI ID = 0.0 >
[215]
[216] (Wherein the symbols are as defined above),
[217] Oxidizing compound (XXII) to obtain a compound of formula (XXIII): < EMI ID =
[218]
[219] (Wherein the symbols are as defined above),
[220] Can then be prepared by reacting compound (XXIII) with a compound of formula (XXIV)
[221] R ⁶ -H
[222] (Wherein R < ⁶ > is as defined above).
[223] C method
[224] The compound (I-a) can be obtained by reacting a compound of the formula (XXV), which is obtained by removing the protecting group R ⁵ for the carboxyl group of the compound (IV)
[225]
[226] (Wherein the symbols are as defined above),
[227] With a compound (IX-a) to obtain a compound of the formula (XXVI-a): < EMI ID =
[228]
[229] (Wherein the symbols are as defined above),
[230] Oxidizing the compound (XXVI-a) to obtain a compound of the formula (XXVI-a): < EMI ID =
[231]
[232] (Wherein the symbols are as defined above),
[233] Subsequently, the compound (XXVI-a) can be produced by reacting the compound (VIVI).
[234] D method
[235] Compound (I-b) can be prepared by oxidizing a compound of formula (XXVII), which is obtained by reacting compound (XVII) with a metal salt of compound (IX-
[236]
[237] (Wherein the symbols are as defined above)
[238] To obtain a compound of formula (XXVI-b): < EMI ID =
[239]
[240] (Wherein the symbols are as defined above),
[241] Further oxidizing the compound (XXVI-b) to obtain a compound of the formula (XXVI-b): < EMI ID =
[242]
[243] (Wherein the symbols are as defined above),
[244] Subsequently, the compound (XXVI-b) can be produced by reacting the compound (VIVI).
[245] E method
[246] The compound (I-b) can be obtained by oxidizing the compound of the formula (XXX), which is obtained by reacting the dihalogeno compound (XI) with a compound of the formula
[247] R ¹² -CHO
[248] (Wherein R < ¹² > is as defined above)
[249]
[250] (Wherein the symbols are as defined above)
[251] To obtain a compound of formula < RTI ID = 0.0 > (XXXI) <
[252]
[253] (Wherein the symbols are as defined above),
[254] Reacting compound (XXXI) with compound (III) to obtain a compound of formula (XXXII): < EMI ID =
[255]
[256] (Wherein the symbols are as defined above),
[257] Then, the compound (XXXII) can be produced by reacting it with the compound (VI).
[258] Further, the compound (XXXII) can be obtained by reacting the compound (XXX) with the compound (III) to obtain a compound of the formula (XXXIII)
[259]
[260] (Wherein the symbols are as defined above),
[261] Then, it can be prepared by oxidizing the compound (XXXIII).
[262] F method
[263] Compound (I-a) can be produced by reacting compound (XIII) with a compound of formula (XXXIV)
[264] RSH
[265] (Wherein R is a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted aryl group)
[266] To obtain a compound of formula XXXV: < RTI ID = 0.0 >
[267]
[268] (Wherein the symbols are as defined above),
[269] Reacting compound (XXXV) with compound (VI) or a salt thereof to obtain a compound of formula (XXXVI)
[270]
[271] (Wherein the symbols are as defined above),
[272] Removal of the protecting group R < ⁵ > for the carboxyl group of the compound (XXXVI) to give a compound of the formula XXXVI &
[273]
[274] (Wherein the symbols are as defined above),
[275] Reacting compound (XXXVII) with compound (IX-a) to obtain a compound of formula (XXXIX): <
[276]
[277] (Wherein the symbols are as defined above),
[278] The compound (XXXIX) is oxidized to give a sulfonyl or sulfinyl compound,
[279] Subsequently, the product can be prepared by reacting it with compound (III).
[280] Method A to Method F can be carried out as follows.
[281] Method A
[282] The reaction of the compound (II) with the compound (III) is carried out in a solvent in the presence or absence of a deoxidizing agent. The deoxidizing agent may be an organic base such as, for example, an organic base such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine or pyridine, an inorganic base such as sodium hydride, sodium carbonate, potassium carbonate, . The solvent may be any solvent which does not inhibit the reaction such as dimethyl sulfoxide, tetrahydrofuran, toluene, ethyl acetate, chloroform, dimethoxyethane, xylene, N, N-dimethylformamide and the like. The reaction is carried out at a temperature of from -10 ° C to room temperature, preferably from 0 ° C to room temperature.
[283] The reaction of oxidizing the compound (IV) to obtain a sulfonyl (or sulfinyl) compound (V) is carried out in a solvent in the presence of an oxidizing agent. Oxidizing agents include, for example, peroxides such as m-chloroperbenzoic acid, peracetic acid and the like, and organic peroxides such as manganese dioxide, sodium periodate, hydrogen peroxide, tetraoxide, halogen, hydroperoxide, iodobenzene, acetate, hypochlorous acid t -Butyl, sulfuryl chloride, potassium peroxymonosulfate, and the like. The solvent may be any solvent which does not inhibit the reaction of, for example, chloroform, methylene chloride, dichloroethane, acetic acid and the like. The reaction is carried out at a temperature of from -78 ° C to 50 ° C, preferably from -10 ° C to 10 ° C.
[284] The reaction of the compound (V) with the compound (VI) or its salt can be carried out in a solvent in the presence or absence of a deoxidizing agent. Deoxidizing agents include inorganic bases such as organic bases such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, pyridine and the like, sodium hydride, sodium carbonate, potassium carbonate, sodium hydrogencarbonate and the like do. The salt of the compound (VI) is preferably an alkali metal salt such as a sodium salt or a potassium salt. The solvent may be any solvent which does not inhibit the reaction such as, for example, N, N-dimethylformamide, tetrahydrofuran, dimethoxyethane, dimethylsulfoxide and the like. The reaction is carried out at a temperature of from 0 ° C to 150 ° C, preferably from room temperature to 60 ° C. The reaction for removing the protecting group R ⁵ for the carboxyl group of the compound (VII) to obtain the compound (VIII) can be carried out by a conventional method such as hydrolysis, catalytic reduction and the like, It is selected according to the type. When the protecting group for the carboxyl group is removed by hydrolysis, the hydrolysis is carried out in a solvent, for example, in the presence of a base. The base is preferably an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, lithium hydroxide or the like, or an alkali metal carbonate such as sodium carbonate, potassium carbonate and the like. The solvent may be water or a mixture of water and methanol, ethanol, tetrahydrofuran, dioxane, N, N-dimethylformamide, dimethylsulfoxide and the like. The reaction is carried out at a temperature of from 0 to 80 캜, preferably from 5 to 60 캜. The protecting group for the carboxyl group represented by R < ⁵ > may be any conventional protecting group for a carboxyl group such as a lower alkyl group, a benzyl group and the like.
[285] The reaction of the compound (VIII) with the compound (IX-a) can be carried out in a suitable solvent in the presence or absence of a condensing agent, a base or an activating agent. Examples of the condensing agent include dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethyl-aminopropyl) carbodiimide, diphenylphosphoryl azide, diethylcyano- , Which are generally used in peptide synthesis. The base includes, for example, organic bases such as triethylamine, N-methylmorpholine and the like, and the activator includes, for example, 1-hydroxybenzotriazole and the like. The solvent may be any solvent which does not inhibit the reaction such as methylene chloride, tetrahydrofuran, N, N-dimethylformamide, acetonitrile, N, N-dimethylacetamide, ethyl acetate and the like. The reaction is carried out at a temperature of from -30 ° C to 50 ° C, preferably from -10 ° C to 10 ° C.
[286] An alternative method of converting compound (VIII) to compound (X) followed by further reaction with compound (IX-a) is to first react compound (VIII) with a halogenating agent in the presence or absence of an activating agent , And reacting the resulting compound (X) with compound (IX-a). The reaction of the compound (VIII) with a halogenating agent is carried out in a solvent. The halogenating agent is preferably thionyl chloride, oxalyl chloride, phosphorus pentachloride, or the like. The activating agent is preferably an amide compound such as N, N-dimethylformamide. The solvent may be any solvent which does not inhibit the reaction of, for example, methylene chloride, chloroform, tetrahydrofuran, benzene, toluene, dioxane and the like. The reaction is carried out at a temperature of from -30 캜 to 100 캜, preferably from-5 캜 to 10 캜.
[287] The reaction with compound (IX-a) is then carried out in the presence of a deoxidizing agent in a solvent. The deoxidizing agent is, for example, an organic base such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine, pyridine, dimethylaminopyridine and the like, and an organic base such as sodium hydride, sodium carbonate, potassium carbonate, And includes the same inorganic base. The solvent may be any solvent which does not inhibit the reaction such as tetrahydrofuran, methylene chloride, chloroform, toluene, benzene, dioxane, ethyl acetate and the like. The reaction is carried out at a temperature of from -30 캜 to 100 캜, preferably from-5 캜 to 10 캜.
[288] The reaction of treating the dihalogeno compound (XI) with carbon dioxide to obtain the compound (XII) can be carried out in a solvent in the presence of a base. The base includes, for example, alkali metal salts of organic bases such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, and the like. The solvent may be any solvent which does not inhibit the reaction of, for example, tetrahydrofuran, 1,2-dimethoxyethane, diethyl ether or the like. The reaction is carried out at a temperature of -100 ° C to -30 ° C, preferably -100 ° C to -70 ° C.
[289] When the protecting group is a lower alkyl group, the reaction for obtaining the compound (XIII) by protecting the carboxyl group of the compound (XII) can be carried out by a conventional method, for example, by reacting with an alkylating agent in a solvent in the presence of a base. The alkylating agent is preferably a lower alkyl halide such as methyl iodide. The base is preferably an alkali metal hydrogencarbonate such as sodium hydrogencarbonate, and the solvent may be any solvent which does not inhibit the reaction such as, for example, N, N-dimethylformamide, tetrahydrofuran and the like. The reaction is carried out at a temperature of from 0 ° C to 100 ° C, preferably from room temperature to 70 ° C.
[290] The reaction of reacting the compound (XIII) with the compound (III) to obtain the compound (XIV) can be carried out in the same manner as the reaction of the compound (II) and the compound (III).
[291] The reaction of compound (XIV) with compound (VI) to obtain compound (VII) can be carried out in the same manner as the reaction of compound (V) with compound (VI).
[292] The reaction of hydrolyzing compound (V) to obtain compound (XV) can be carried out in a solvent in the presence of a base. The base includes, for example, alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, lithium hydroxide and the like, and alkali metal carbonates such as sodium carbonate and potassium carbonate. The solvent is preferably water or a mixture of water with methanol, ethanol, tetrahydrofuran, dioxane, N, N-dimethylformamide, dimethylsulfoxide and the like. The reaction is carried out at a temperature of from -20 캜 to 80 캜, preferably from -5 캜 to 60 캜.
[293] The reaction of halogenating compound (XV) to obtain compound (XIV) can be carried out in the same manner as in the reaction of halogenating compound (XIII) by halogenating agent to obtain compound (X).
[294] Method B
[295] The reaction of reducing compound (IV) to obtain compound (XVI) can be carried out in the presence of a reducing agent and in a suitable solvent. As the reducing agent, a hydrogenated aluminum alkali metal such as lithium aluminum hydride and an alkali metal borohydride such as lithium borohydride are preferable. The solvent may be any solvent that does not inhibit the reaction such as, for example, tetrahydrofuran, dioxane, diethyl ether, dimethoxyethane, etc. The reaction may be carried out at a temperature of from -78 ° C to the boiling point of the solvent used, Is carried out at a temperature of from -10 [deg.] C to room temperature.
[296] The reaction of oxidizing the compound (XVI) to obtain the compound (XVII) can be carried out in a solvent in the presence of an oxidizing agent. The oxidizing agent may be an alcohol, such as manganese dioxide, barium permanganate, potassium permanganate, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, pyridinium chlorochromate, pyridinium dichloromate, Compound < / RTI > The solvent may be any solvent that does not inhibit the reaction, such as chloroform, toluene, ethyl acetate, 1,2-dichloroethane, methylene chloride, tetrahydrofuran and the like. The reaction is carried out at a temperature of from 0 ° C to 100 ° C, preferably from room temperature to 70 ° C.
[297] The reaction of oxidizing the compound (XVII) to obtain the compound (XVIII) is carried out in the same manner as in the reaction of obtaining the compound (V) by oxidizing the compound (IV).
[298] The reaction of compound (XVII) with compound (VI) to obtain compound (XIX) is carried out in the same manner as in the reaction of compound (V) and compound (IV).
[299] The reaction of compound (XIX) with a metal salt of compound (IX-b) to give compound (XX) can be carried out in a suitable solvent. The metal salt of the compound (IX-b) is preferably a lithium salt or the like. The solvent may be any solvent which does not inhibit the reaction such as, for example, tetrahydrofuran, dioxane, diethyl ether, dimethoxyethane and the like. The reaction can be preferably carried out at a temperature of from -78 ° C to room temperature.
[300] The reaction of oxidizing the compound (XX) to obtain the compound (I-b) can be carried out in the same manner as in the reaction of obtaining the compound (XVII) by oxidizing the compound (XVI).
[301] The reaction of compound (XIX) with Grignard compound (XXI) can be carried out in a suitable solvent. As the solvent, tetrahydrofuran, dioxane, diethyl ether and the like are preferable. The reaction can be preferably carried out at a temperature of -78 ° C to 60 ° C, preferably at a temperature of -78 ° C to room temperature.
[302] The reaction of oxidizing the compound (XXII) to obtain the compound (XXIII) is carried out in the same manner as in the reaction of obtaining the compound (XVII) by oxidizing the compound (XVI).
[303] Compound (XXⅢ) and R ⁶ is morpholino group, 4-lower alkyl-piperazinyl group, a 3-pyridyl group, 2-pyrimidinyl-lower alkyl group, or a di-lower alkylamino group reacting a compound (XXⅣ) (I-c) wherein R ⁶ is a morpholino group, a 4-lower alkylpiperazinyl group, a 3-pyridylamino group, a 2-pyrimidinyl-lower alkylamino group or a di- Can be carried out in the presence or absence of a base in a suitable solvent. The base is, for example, an organic base such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine or pyridine, or an inorganic base such as sodium hydroxide, sodium carbonate, potassium carbonate, . The solvent may preferably be ethanol, N, N-dimethylformamide, tetrahydrofuran, dimethoxyethane, dimethylsulfoxide, etc. The reaction is carried out at a temperature of from 0 ° C to 150 ° C, preferably from room temperature to 60 ° C .
[304] On the other hand, compound (XXⅢ) and R ⁶ is by reacting a hydroxy group or a lower alkoxy group compound (XXⅣ), R ⁶ is, without a solvent or in an appropriate solvent and the reaction to give the hydroxy group or a lower alkoxy group compound (XXI) in the presence of an acid Can be performed. The acid includes, for example, an inorganic acid such as sulfuric acid or an organic acid such as methanesulfonic acid, camphorsulfonic acid, toluenesulfonic acid, and benzenesulfonic acid. The solvent may preferably be diethyl ether, toluene, benzene, N, N-dimethylformamide, dimethoxyethane, dimethylsulfoxide and the like. The reaction may be carried out at a temperature of from 0 ° C to 150 ° C, preferably from room temperature to 60 ° C.
[305] C method
[306] The reaction for obtaining the compound (XXV) by removing the protecting group R ⁵ for the carboxyl group of the compound (IV) is carried out in the same manner as in the reaction for obtaining the compound (VIII) by removing the protecting group R ⁵ for the carboxyl group of the compound . ≪ / RTI >
[307] The reaction of compound (XXV) with compound (IX-a) to give compound (XXVI-a) can be carried out in the same manner as in the reaction of compound (VIII) with compound (IX-a).
[308] The reaction of oxidizing the compound (XXVI-a) to obtain the compound (XXVI-a) can be carried out in the same manner as in the reaction of obtaining the compound (V) by oxidizing the compound (IV).
[309] The reaction of obtaining compound (I-a) of the present invention by reacting compound (XXVII-a) with compound (VI) can be carried out in the same manner as in the reaction of compound (V) with compound (VI).
[310] D method
[311] The reaction of compound (XVII) with a metal salt of compound (IX-b) to give compound (XXVIII) can be carried out in the same manner as in the reaction of compound (XIX) with a metal salt of compound (IX-b) .
[312] The reaction of oxidizing the compound (XXVII) to obtain the compound (XXVI-b) can be carried out in the same manner as in the reaction of obtaining the compound (XVII) by oxidizing the compound (XVI).
[313] The method of oxidizing the compound (XXVI-a) to obtain the compound (XXVI-b) and further converting it into the compound (I-b) of the present invention can be carried out by oxidizing the compound (XXVI- ) And then converting it into the compound (I-a) of the present invention.
[314] E method
[315] The reaction of compound (XI) with compound (XXIX) to obtain compound (XXX) is carried out in the presence of a base in a suitable solvent. The base includes, for example, alkali metal salts of organic bases such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, and the like. The solvent may be any solvent which does not inhibit the reaction of, for example, tetrahydrofuran, 1,2-dimethoxyethane, diethyl ether or the like. The reaction is carried out at a temperature of -100 ° C to -30 ° C, preferably -100 ° C to -70 ° C.
[316] The reaction of oxidizing the compound (XXX) to obtain the compound (XXXI) can be carried out in the same manner as in the reaction of obtaining the compound (XVII) by oxidizing the compound (XVI).
[317] The reaction of compound (XXXI) with compound (III) to obtain compound (XXXII) can be carried out in the same manner as in the reaction of compound (II) and compound (III).
[318] The reaction of obtaining Compound (I-b) of the present invention by reacting Compound (XXXII) with Compound (VI) or a salt thereof can be carried out in the same manner as in the reaction of Compound (V) with Compound .
[319] The reaction of compound (XXX) with compound (III) to obtain compound (XXXIII) can be carried out in the same manner as in the reaction of compound (II) and compound (III). The reaction of oxidizing the compound (XXXIII) to obtain the compound (XXXII) can also be carried out in the same manner as in the reaction of obtaining the compound (XVII) by oxidizing the compound (XVI).
[320] F method
[321] The reaction of the compound (XIII) with the compound (XXXIV) can be carried out in a solvent in the presence or absence of a deoxidizing agent. The deoxidizing agent may be an organic base such as, for example, an organic base such as N, N-diisopropylethylamine, N-methylmorpholine, triethylamine or pyridine, an inorganic base such as sodium hydride, sodium carbonate, potassium carbonate, . The solvent may be any solvent which does not inhibit the reaction such as, for example, N, N-dimethylformamide, tetrahydrofuran, toluene, ethyl acetate, chloroform, dimethoxyethane, xylene, dimethylformamide and the like. The reaction is carried out at a temperature of from -10 ° C to room temperature, preferably from 0 ° C to room temperature.
[322] The reaction of the compound (XXXV) with the compound (VI) or its salt can be carried out in the same manner as in the reaction of the compound (V) with the compound (VI).
[323] The reaction for obtaining the compound (XXXVII) by removing the protecting group R ⁵ for the carboxyl group of the compound (XXXVI) is carried out in the same manner as in the reaction for obtaining the compound (VIII) by removing the protecting group R ⁵ for the carboxyl group of the compound (VII) . ≪ / RTI >
[324] The reaction of compound (XXXVII) with compound (IX-a) can be carried out in the same manner as in the reaction of compound (VIII) with compound (IX-a).
[325] The oxidation reaction of the compound (XXXIX) can be carried out in the same manner as the reaction of the compound (IV) which gives the compound (V). The oxidizing agent is preferably m-chloroperbenzoic acid or the like. The solvent may be any solvent which does not inhibit the reaction of, for example, chloroform, methylene chloride, dichloroethane, acetic acid and the like. The reaction is carried out at a temperature of from -78 ° C to 50 ° C, preferably from -10 ° C to 10 ° C.
[326] The reaction with the continuous compound (III) can be carried out in the same manner as in the reaction of the compound (II) with the compound (III).
[327] The compound (I) thus obtained can be converted into its pharmaceutically acceptable salt.
[328] The starting compound (II) can be prepared, for example, by the method described in Journal of American Chemical Society, p. 350, vol. 65, 1943).
[329] Examples of compound (I) of the present invention which can be prepared by the above exemplified method are described below, but should not be construed as limiting the present invention.
[330] Example 1
[331] (1) To a solution of 4-chloro-5-ethoxycarbonyl-2-methylthio-pyrimidine (25.33 g) in N, N-dimethylformamide (85 ml) was added N, N-dimethylformamide chloro-4-methoxybenzylamine (19.62 g) and triethylamine (16.7 ml) in anhydrous tetrahydrofuran (2 ml) under ice cooling (ice cooling). The mixture was stirred at room temperature for 20 minutes, 3-chloro-4-methoxybenzylamine (940 mg) was added thereto, and the mixture was stirred for an additional 15 minutes. To the mixture was added the above amine (940 mg) and the mixture was stirred for 15 minutes. The reaction mixture was poured into a mixture of cold water and citric acid, and the mixture was extracted with ethyl acetate. The extract was washed successively with 10% aqueous citric acid solution, water and brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure and the residue was washed with n-hexane to give 4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonyl-2-methyl-thiopyrimidine (38.34 g) , And a melting point of 86 占 폚 was obtained.
[332] (2) To a solution of the compound obtained in (1) above (5.00 g) in chloroform (50 ml) was added a solution of m-chloroperbenzoic acid (4.00 g) in chloroform (50 ml) under ice- And stirred for 2 hours. The reaction mixture was washed with a saturated aqueous sodium hydrogen carbonate solution and brine and the organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated under reduced pressure to give the crude product 4- (3-chloro-4-methoxybenzylamino) -5- Ethoxycarbonyl-2-methylsulfinylpyrimidine, MS (m / z): 447 (MH ⁺ ).
[333] (3) The crude product obtained in the above (2) was dissolved in tetrahydrofuran (40 ml), and thereto was added L-proprolol (1.50 g) and triethylamine (1.60 g, ) Was added at room temperature. The mixture was stirred overnight, and the reaction mixture was diluted with ethyl acetate, washed with aqueous sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: chloroform) and crystallized from a mixture of ether and n-hexane to give (S) -4- (3-chloro-4-methoxybenzylamino) (M / z): 421 (MH < ⁺ & gt ^; ) as a colorless oil.
[334] (4) A mixture of the compound (3.4 g) obtained in the above (3), 10% aqueous sodium hydroxide solution (23 ml) and dimethyl sulfoxide (34 ml) was stirred at room temperature for 15 hours. The reaction mixture was poured into 10% aqueous citric acid solution and the precipitate was crystallized from a mixture of tetrahydrofuran and ether to give (S) -4- (3-chloro-4-methoxybenzylamino) (2.52 g) and a melting point of 205-208 占 폚, MS (m / z): 391 (MH) ^- .
[335] (5) The compound (600 mg) obtained in the above (4), 2-aminomethylpyrimidine (217 mg) and 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (323 mg) , 1-hydroxybenzotriazole monohydrate (227 mg) and N, N-dimethylformamide (12 ml) was stirred at room temperature for 8 hours, and the reaction mixture was poured into aqueous sodium hydrogencarbonate solution. The mixture was extracted with ethyl acetate, washed with brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (solvent: chloroform: methanol = 50: 1) to obtain (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- -5- [N- (2-pyrimidylmethyl) carbamoyl] pyrimidine (610 mg) and a melting point of 160-163 ° C.
[336] Example 2
[337] (1) To a suspension of lithium aluminum hydride (4.15 g) in tetrahydrofuran (150 ml) was added a solution of 2-methylthio-4- (3-chloro-4- methoxybenzylamino) A solution of 5-ethoxycarbonylpyrimidine (38.32 g) was added under ice-cooling at 5 ° C to 10 ° C over 1 hour. After the addition, the ice bath was removed and the reaction mixture was stirred at room temperature for 1 hour. To the reaction mixture, water (4.15 ml) was added under ice-cooling, and thereto was further added a 3N aqueous solution of sodium hydroxide (4.15 ml). To the mixture was added water (4.15 ml) 3 times, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was treated with magnesium sulfate and the solid precipitate obtained was filtered. The precipitate was washed with tetrahydrofuran. The filtrate and washings are combined, concentrated under reduced pressure and triturated with a mixture of ethyl acetate and isopropyl ether. The resulting crystals were collected by filtration and sufficiently washed with isopropyl ether to obtain 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-hydroxymethylpyrimidine as pale yellow crystal powder .
[338] 1st generation: Yield; 25.10 g, melting point 162-163 DEG C
[339] 2nd generation: yield; 2.32 g, melting point 159-160 DEG C
[340] The solid precipitate was further washed with isopropyl ether and the filtrate was concentrated under reduced pressure to obtain colorless crystals. The resulting solid was suspended in isopropyl ether, filtered and the precipitate washed well with isopropyl ether and hexane to give 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5- Methylpyrimidine (4.26 g) as colorless crystals, mp 161-162 ° C.
[341] (2) To a suspension of 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-hydroxymethylpyrimidine (25.10 g) obtained in the above (1) in chloroform (150 ml) , Manganese dioxide powder (37.6 g) was added and the mixture stirred vigorously at room temperature for one day. To the mixture was further added manganese dioxide (12.6 g, 0.5 times the amount of the starting compound) and the mixture was stirred for 3 days. Insoluble material was quickly removed by celite filtration and the filtrate was concentrated under reduced pressure. The residue was suspended in a mixture of ethyl acetate and isopropyl ether. The precipitate was filtered and washed successively with isopropyl ether and hexane to give 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-formylpyrimidine (22.43 g) as colorless crystals, Mp 124-125 < 0 > C.
[342] (3) A solution of 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-formylpyrimidine (2.057 g) in chloroform (20 ml) Was treated with chloroperbenzoic acid (80%, 1.468 g). To the reaction mixture was added L-prolinol (0.901 g), followed by triethylamine (1.33 ml), and the mixture was reacted at 0 ° C for 1 hour. The reaction mixture was allowed to warm to room temperature and diluted with ethyl acetate. The mixture was successively washed with a saturated aqueous sodium hydrogen carbonate solution, water and saturated aqueous sodium chloride solution, and dried over anhydrous sodium sulfate. The precipitate was filtered off through a silica plug. The filtrate was concentrated under reduced pressure to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3- chloro-4- methoxybenzylamino) -5-formylmyrimidine ) As colorless amorphous, MS (m / z): 377 (MH ⁺ ).
[343] (4) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) (91.0 mg), a 1.10 M solution of methyllithium in ether (1.1 ml) was added at -78 [deg.] C, the mixture was allowed to react for 10 minutes, and an aqueous solution of sodium hydrogencarbonate was added thereto. The reaction mixture was extracted with ethyl acetate to give the crude product (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) Hydroxyethyl) pyrimidine, MS (m / z): 393 (MH ⁺ ).
[344] (5) The crude product obtained in the above (4) was treated with manganese dioxide (0.5 g) at room temperature, and the mixture was stirred overnight. The reaction mixture was heated under reflux for 5 hours and the insoluble material was removed by filtration. The filtrate was concentrated under reduced pressure and purified by silica gel column chromatography (solvent: chloroform: ethyl acetate = 3: 1) to obtain (S) - (2- hydroxymethyl-1-pyrrolidinyl) -4- Methoxybenzylamino) -5-acetylpyrimidine (56.7 mg) as a colorless oil, MS (m / z): 391 (MH ⁺ ).
[345] Example 3
[346] (1) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- To a solution of m-pyrimidine (84 mg), a 1.0 M solution of magnesium bromide in tetrahydrofuran was added dropwise in a dry ice acetone bath. The reaction mixture was stirred at -78 < 0 > C for 10 min and at room temperature for 10 min. The reaction mixture was poured into a mixture of ice and saturated aqueous sodium hydrogen carbonate solution, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure.
[347] The obtained crude product was purified by preparative thin layer chromatography (solvent: ethyl acetate: methanol = 20: 1) to give (S) -2- (2- hydroxymethyl- 1- pyrrolidinyl) -4- (30 mg) was obtained as a colorless oil, MS (m / z): 405 (MH < ⁺ & gt ^; ) .
[348] (2) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- Hydroxy-2-propen-1-yl) pyrimidine (144 mg), manganese dioxide (432 mg) was added and the mixture stirred vigorously at room temperature for 3 days. The insoluble material was filtered off with celite, and the filtrate was concentrated under reduced pressure to give a pale yellow oil (124 mg). The resulting crude product was purified by silica gel column chromatography (silica gel, 20 g, solvent: chloroform: ethyl acetate = 2: 1) to obtain (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (90 mg) was obtained as colorless crystals, melting point 113-115 ° C, MS (m / z): 403 (MH ⁺ ). did.
[349] (3) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) ) Pyrimidine (72 mg), morpholine (78 L) was added at room temperature, and the mixture was stirred at room temperature for 40 minutes. The reaction mixture was concentrated under reduced pressure, the residue was poured into water, and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water and brine, dried over anhydrous magnesium sulfate and concentrated to dryness under reduced pressure to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (4-methoxybenzylamino) -5 - [(2-morpholinoethyl) carbonyl] -pyrimidine (91 mg).
[350] The crude product obtained was dissolved in ethyl acetate (10 ml) and the solution was treated with a saturated solution of hydrochloric acid in methanol (5 ml) and concentrated under reduced pressure. Ethyl acetate was added to the residue, and the mixture was filtered. The resultant solid was sufficiently washed with hexane to obtain (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) (Morpholinoethyl) carbonyl] -pyrimidine dihydrochloride (65 mg), MS (m / z): 490 (MH ⁺ ).
[351] Example 4
[352] To a solution of 4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonyl-2-methylthiopyrimidine (972 mg) obtained in Example 1- (1) Was added a solution of m-chloroperbenzoic acid (80%, 598 mg) in chloroform (10 ml) under ice-cooling over 30 minutes. The reaction mixture was stirred under ice-cooling for 1 hour. The reaction mixture was diluted with a saturated aqueous solution of sodium hydrogencarbonate, the chloroform layer was collected, washed successively with a saturated aqueous solution of sodium hydrogen carbonate, water and saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2- Methoxybenzylamino) -5-ethoxycarbonylpyrimidine was quantitatively obtained as colorless caramel, MS (m / z): 384 (MH ^< ⁺ & gt ^; ).
[353] (2) To a solution of 2-methylsulfinyl-4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonylpyrimidine (total amount) obtained in the above (1) in tetrahydrofuran Was added a 2N aqueous sodium hydroxide solution (1.32 ml) dropwise over 2 minutes under ice-cooling. The reaction mixture was stirred for 30 minutes under ice-cooling, and thereto was added tetrahydrofuran (8 ml) and N, N-dimethylacetamide (6 ml). The reaction mixture was stirred under ice-cooling for 30 minutes, water (5 ml) and N, N-dimethylacetamide (2 ml) were added thereto, and the mixture was stirred for 1 hour under ice-cooling. The reaction mixture was acidified with a 10% aqueous citric acid solution, diluted with water and extracted twice with ethyl acetate. The extracts were combined, washed with water and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was separated by silica gel column chromatography (silica gel: 20 g, solvent: chloroform: ethyl acetate = 5: 1 → chloroform: isopropanol = 30: 1) to obtain 2-hydroxy- -5-ethoxycarbonylpyrimidine (618 mg) was obtained as pale yellow crystalline powder, melting point 195-197 ° C.
[354] (3) To a solution of the 2-hydroxy-4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonylpyrimidine (500 mg) obtained in the above (2), diethylaminobenzene ) And phosphorus oxychloride (4 ml) was stirred at 80 < 0 > C for 30 minutes and at 100 < 0 > C for 5 hours. After cooling, the reaction solution was poured into ice water, and the mixture was stirred at room temperature for 30 minutes. The resulting mixture was extracted with ethyl acetate and the organic layer was washed with water and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel: 7 g, solvent: chloroform) to obtain 375 mg (yield: 37%) of 2-chloro-4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonylpyrimidine ) As a light yellow crystalline powder, melting point 114-115 占 폚, MS (m / z): 356 (MH ⁺ ).
[355] (4) 285 mg of 2-chloro-4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonylpyrimidine obtained in (3) A mixture of tetrahydroimidazo [1,2-a] pyrazine (197 mg), triethylamine (0.22 ml) and chloroform (3 ml) was stirred at room temperature for 2.5 hours and at 60 ° C for 2.5 hours. The reaction mixture was diluted with ethyl acetate and washed with water. The aqueous layer was extracted with ethyl acetate and the organic layer was washed with water and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (silica gel: 10 g, solvent: chloroform: methanol = 50: 1) and concentrated under reduced pressure. The product was triturated with isopropyl ether to give 2- (5,6,7,8-tetrahydroimidazo [1,2- a] pyrazin-7-yl) -4- (3- Benzylamino) -5-ethoxycarbonylpyrimidine (290 mg) as a colorless crystal powder with a melting point of 179-182 캜, MS (m / z): 443 (MH ⁺ ).
[356] (5) To a solution of 2- (5,6,7,8-tetrahydroimidazo [1,2-a] pyrazine obtained in (4) above) in a mixture of dimethyl sulfoxide (5 ml) 5-ethoxycarbonylpyrimidine (290 mg) and a 2N aqueous sodium hydroxide solution (1.64 ml) was stirred at room temperature for 1 hour Lt; / RTI > Tetrahydrofuran (5 ml) was added to the mixture, and the mixture was stirred at room temperature for 13 hours. Tetrahydrofuran was evaporated under reduced pressure, and the resulting solution was diluted with water and neutralized with a 10% aqueous citric acid solution. The precipitate was collected by filtration and washed with water, methanol and isopropyl ether to give 2- (5,6,7,8-tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- to obtain a ^- 413 (MH): 3- chloro-4-methoxybenzyl) -5-carboxy-pyrimidine (187 mg) as a colorless crystalline powder, melting point 223-226 ℃ (decomposed), MS (m / z) .
[357] (6) Synthesis of 2- (5,6,7,8-tetrahydroimidazo [1,2- a] pyrazin-7-yl) -4- (3-chloro-4-methoxybenzylamino) (60 mg), 4-methyl-2-aminomethylmorpholine (22.7 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (30.6 mg) Triazole (21.6 mg) and N, N-dimethylformamide (3 ml) was stirred at room temperature for 22 hours. Water was poured into the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed successively with water, saturated aqueous sodium hydrogen carbonate solution, water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give colorless crystals (70.0 mg) which were further recrystallized from a mixture of chloroform and hexane to give 2 - (5,6,7,8-tetrahydroimidazo [1,2- a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) Methyl-2-morpholinyl) methyl] carbamoyl] pyrimidine (51.7 mg) as a colorless needle, mp 132-134 캜, MS (m / z): 527 (MH ⁺ ).
[358] Examples 5-6
[359] The corresponding starting materials were treated in a similar manner as in Example 4- (6) to give the compounds listed in Table 1 below.
[360]
[361]
[362] Examples 7-21
[363] The corresponding starting materials were treated in a similar manner to give the compounds listed in Table 2 below.
[364]
[365]
[366]
[367] Example 22
[368] To a solution of diisopropylamine (0.78 g) in tetrahydrofuran (40 ml) was added dropwise a 1.6 M solution of n-butyllithium in hexane (4.82 ml) over 3 minutes in a dry ice acetone bath. The mixture was stirred in the same tank for 30 minutes. To the mixture was added dropwise a solution of 2,6-dichloropyrazine (0.50 g) in tetrahydrofuran (5 ml) at the same temperature over 15 minutes, and the mixture was stirred for 1 hour. The reaction mixture was poured into dry ice, and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with a 10% aqueous hydrochloric acid solution to adjust its pH value to about 2, and extracted with ethyl acetate. The combined organic layers were extracted with saturated aqueous sodium hydrogen carbonate solution, the aqueous extracts were washed with ethyl acetate, acidified with 10% aqueous hydrochloric acid and extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous solution of sodium chloride, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was triturated with a mixture of chloroform and hexane (1: 1) to give 2-carboxy-3,5-dichloropyrazine (234 mg) as pale brown crystalline powder, : 191 (MH) ^- .
[369] (2) To a solution of 2-carboxy-3,5-dichloropyrazine (226 mg), sodium hydrogencarbonate (118 mg), methyl iodide (0.5 ml) and N, N-dimethylformamide ) Was stirred at room temperature for 14 hours. The mixture was diluted with a 10% aqueous citric acid solution and extracted with ethyl acetate. The combined organic layers were washed with water and a saturated aqueous sodium chloride solution, dried over anhydrous sodium sulfate and concentrated under reduced pressure to give 2-methoxycarbonyl-3,5-dichloropyrazine (245 mg) as a pale brown crystalline powder, , MS (m / z): 206 (M ⁺ ).
[370] (3) To a mixture of 234 mg of 2-methoxycarbonyl-3,5-dichloropyrazine obtained in the above (2), 204 mg of 3-chloro-4-methoxybenzylamine, 0.17 ml of triethylamine, And dry toluene (3 ml) was stirred at room temperature for 7 hours. The reaction mixture was diluted with a 10% aqueous citric acid solution and extracted with ethyl acetate. The extract was washed with water and a saturated aqueous solution of sodium chloride, dried over sodium sulfate and concentrated under reduced pressure. The residue was separated and purified by silica gel column chromatography (silica gel: 5 g, solvent: hexane: chloroform = 1: 1), and the objective fraction was concentrated under reduced pressure to obtain 2-methoxycarbonyl- 5-chloropyrazine (102 mg) was obtained as a pale yellow crystal powder, melting point 149-151 占 폚, MS (m / z): 342 (MH ⁺ ).
[371] (5) To a mixture of 2-methoxycarbonyl-3- (3-chloro-4-methoxybenzylamino) -5- chloropyrazine (150 mg), 2- hydroxymethylpyrrolidine A mixture of amine (0.12 ml) in tetrahydrofuran (5 ml) was stirred at room temperature for 4 hours and the mixture was heated at 50 ° C for 2 hours. To the mixture was added 2-hydroxymethylpyrrolidine (44.3 mg), and the mixture was stirred at 50 占 폚 for 1 hour. After cooling, water was added to the reaction mixture and the mixture was extracted with ethyl acetate. The extract was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting yellow oil was purified by silica gel column chromatography (solvent: chloroform: hexane = 1: 1) to obtain (S) -2-methoxycarbonyl-3- (3- (123 mg) was obtained as a pale yellow powder, MS (m / z): 407 (MH < ⁺ & gt ^; ).
[372] (5) To a solution of (S) -2-methoxycarbonyl-3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl -1-pyrrolidinyl) -pyrazine (775 mg) in dichloromethane was added 4N aqueous sodium hydroxide solution (1.43 ml), and the mixture was stirred at room temperature for 24 hours. The reaction mixture was acidified with 10% aqueous hydrochloric acid solution and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure and washed with diisopropyl alcohol to give (S) -2-carboxy-3- (3-chloro-4- methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolidinyl) pyrazine (537 mg) as yellow crystals with a melting point of 169-171 캜, MS (m / z): 391 (MH) ^- .
[373] (6) To a solution of (S) -2-carboxy-3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolidinyl) pyrazine obtained in (5) N-dimethylformamide (3 ml) of 2-aminomethylpyrimidine (26.7 mg), 1,2-dichloroethane (43 mg) and 1-hydroxybenzotriazole (30.3 mg) The mixture was stirred at room temperature for 18 hours. Water was poured into the reaction mixture and extracted with ethyl acetate. The extract was washed with water, washed with saturated aqueous sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (solvent: ethyl acetate) to give (S) -2- [N- (2-pyrimidinylmethyl) carbamoyl] -3- (3- Amino) -5- (2-hydroxymethyl-1-pyrrolidinyl) pyrazine (87.6 mg) and MS (m / z): 484 (MH ⁺ ).
[374] Examples 23-24
[375] The corresponding starting materials were treated in a similar manner as in Example 22 to give the compounds listed in Table 3 below.
[376]
[377]
[378] Example 25
[379] (3-chloro-4-methoxybenzylamino) -5- (acryloyl) pyrimidine (31 mg), methanol (1 ml) and concentrated sulfuric acid (1 drop) was heated under reflux for 2 days. After the completion of the reaction, the solvent was evaporated under reduced pressure, and the residue was separated by silica gel thin layer chromatography (solvent: chloroform: methanol = 30: 1) to obtain (S) -2- (2-hydroxymethyl-1-pyrrolidinyl ), Was prepared as colorless oil, MS (m / z): 435 (MH < + >), ⁺ ). ≪ / RTI >
[380] Example 26
[381] To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (82.48 g) and benzenesulfonic acid monohydrate (60.06 g) was concentrated and recrystallized from a mixture of methanol and acetone to obtain (S) -2- (2-hydroxymethylmethylcarbamoylcarbamoylpyrimidine -5- [N- (2-pyrimidinylmethyl) carbamoyl] pyrimidine dibenzenesulfonate (121.8 g) was added to a solution of 4- As colorless crystals, melting point 158.5-161.5 [deg.] C.
[382] Example 27
[383] (S) -4- (3-chloro-4-methoxybenzylamino) -5-carboxy-2- (2-hydroxymethyl-1-pyrrolidinyl) pyrimidine obtained in Example 1- (4) Amino-1,3,5-trimethylpyrazole (47.9 mg), 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (58.7 mg), 1-hydroxy A mixture of benzotriazole monohydrate (41.3 mg) and N, N-dimethylformamide (3 ml) was stirred at room temperature for 8 hours and poured into aqueous sodium hydrogencarbonate solution. The mixture was extracted with ethyl acetate and the organic layer was washed with water and saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (solvent: chloroform: methanol = 5: 1) to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (M / z): < RTI ID = 0.0 > (3-Chloro-4- 500 (MH ⁺ ).
[384] Example 28
[385] (1) A solution of 4-chloro-5-ethoxycarbonyl-2-methylthiopyrimidine (5.0 g) in sulfuric chloride (20 ml) was heated at 50 占 폚 for 1 hour. The reaction mixture was concentrated, and saturated aqueous sodium hydrogen carbonate solution was poured into it. The mixture was extracted with ethyl acetate and the organic layer was washed with water and brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel flash column chromatography (solvent: ethyl acetate: hexane = 1:10) to give 2,4-dichloro-5-ethoxycarbonylpyrimidine (4.87 g) as a yellow oil, MS (m / z): 220 (M ^< ⁺ >).
[386] (2) To a solution of 2,4-dichloro-5-ethoxycarbonylpyrimidine (4.2 g) obtained in the above (1) and mercaptobenzene (2.30 g) in toluene (40 ml) g) was added at 0 占 폚, and the mixture was stirred at room temperature for 1 hour, at 50 占 폚 for 1 hour, and further at 100 占 폚 for 10 minutes. Water was poured into the mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated. The residue was purified by silica gel flash column chromatography (solvent: ethyl acetate: hexane = 1: 20 -> ethyl acetate: hexane = 1: 10) to obtain 2-chloro-4-phenylthio-5-ethoxycarbonylpyrimidine (4.16 g) as colorless crystals, MS (m / z): 295 (MH < ⁺ & gt ^; ).
[387] (3) To a solution of 2-chloro-4-phenylthio-5-ethoxycarbonylpyrimidine (4.05 g) obtained in the above (2) in tetrahydrofuran (40 ml) was added L- g) and triethylamine (2.77 g) were added, and the mixture was stirred at room temperature for 20 hours. Water was poured into the reaction mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (solvent: ethyl acetate: hexane = 1: 2) to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -Ethoxycarbonylpyrimidine (4.16 g) as a colorless viscous oil, MS (m / z): 360 (MH ⁺ ).
[388] (4) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5-ethoxycarbonylpyrimidine ( 4.10 g) was added 4N aqueous sodium hydroxide solution (8.6 ml), and the mixture was stirred at room temperature for 15 hours. To the reaction solution was added 10% citric acid aqueous solution (30 ml) until the solution became slightly acidic, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over sodium sulfate and concentrated to give 3.65 g of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5-carboxypyrimidine As colorless crystals, MS (m / z): 330 (MH) ^- .
[389] (5) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5- A mixture of carboxypyrimidine (2.55 g), 2-aminomethylpyrimidine (1.09 g), 1,2-dichloroethane (1.77 g) and 1-hydroxybenzotriazole (1.25 g) was stirred at room temperature for 16 hours did. Water was poured into the mixture and the mixture was extracted with ethyl acetate. The organic layer was washed with water, a saturated aqueous solution of sodium hydrogencarbonate and brine, dried over sodium sulfate and concentrated to give pale yellow crystals (4.05 g) which was further purified by silica gel flash column chromatography (solvent; ethyl acetate) (2.39 g) was obtained as colorless crystals, melting point 154-145 ° C, from 2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5- [N- (2- pyrimidylmethyl) carbamoyl] pyrimidine 156 占 폚, IR (Nujol): 1633 cm- ¹ , MS (m / z): 423 (MH ⁺ ).
[390] (6) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5- [N- Myrylmethyl) carbamoyl] pyrimidine (100 mg), m-chloroperbenzoic acid (70.1 mg) was added at 0 ° C, and the mixture was stirred at 0 ° C for 30 minutes. 3-Chlorobenzylamine (50.3 mg) and triethylamine (48.0 mg) were added to the mixture at 0 占 and the mixture was stirred at room temperature for 17 hours. Water was poured into the mixture, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give a yellow oil (169 mg) which was purified by silica gel flash column chromatography (solvent; ethyl acetate) and a mixture of ethyl acetate and hexane Trituration to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3- chlorobenzylamino) -5- [N- (2- pyrimidylmethyl) ] Pyrimidine (95.3 mg) as colorless powder, mp 153-156 ° C, IR (Nujol): 3241, 1637 cm ^-1 , MS (m / z): 454 (MH ⁺ ).
[391] (7) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4-phenylthio-5- [N- (70%, 70.1 mg) was added at 0 占 폚, and the mixture was stirred at 0 占 폚 for 30 minutes. To the mixture was added 4-methoxybenzylamine (48.8 mg) and triethylamine (48.0 mg) at 0 占 and the mixture was stirred at room temperature for 20 minutes. The mixture was poured into water, the mixture was extracted with chloroform and the organic layer was washed with brine, dried over sodium sulfate and concentrated to give a yellow oil (143 mg) which was purified by silica gel flash column chromatography (solvent; ethyl acetate) To give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (4- methoxybenzylamino) -5- [N- (2- pyrimidylmethyl) ] Pyrimidine (88.2 mg) as a colorless powder, IR (Neat): 3296, 1633 cm ^-1 , MS (m / z): 450 (MH ⁺ ).
[392] Example 29
[393] (1) To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro- -5-formylpyrimidine (10.0 mg) was treated with a 1.6 M solution of n-butyllithium in hexane (83 占 퐇) at -78 占 폚 for 3 minutes, and thereto was added an aqueous sodium hydrogencarbonate solution Was added. The reaction mixture was extracted with ethyl acetate to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) -5- Pentyl) pyrimidine (13.7 mg) as an oil.
[394] (2) Synthesis of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- ) Pyrimidine was treated with manganese dioxide (25 mg) at room temperature, additional manganese dioxide (100 mg) was slowly added thereto, and the mixture was stirred overnight. The reaction mixture was heated under reflux for 5 hours and the insoluble material was filtered off. The filtrate was concentrated under reduced pressure and the residue was purified by preparative thin layer chromatography to give (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) -5 -Pentanoylpyrimidine (5.8 mg) as a colorless oil, MS (m / z): 433 (MH ⁺ ).
[395] Examples 30-83
[396] The corresponding starting compounds were treated in a similar manner to give the compounds listed in Table 4 below.
[397]
[398]
[399]
[400]
[401]
[402]
[403] Examples 84-86
[404] The corresponding starting compounds were treated in a similar manner to give the compounds listed in Table 5 below.
[405]
[406]
[407] Example 87
[408] To a solution of (S) -2-carboxy-3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxyphenyl) 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride (43 mg) was obtained in the same manner as in Example 1, mg) and 1-hydroxybenzotriazole (30.3 mg) was stirred at room temperature for 18 hours. Water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate. The extract was washed with water, saturated aqueous sodium hydrogen carbonate solution and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel flash column chromatography (solvent: ethyl acetate) to give (S) -2- [N- (4-methyl- 2- morpholinyl) methylcarbamoyl] -3- (3- (80.5 mg), MS (m / z): 505 (MH ⁺ ), IR (Nujol): 3295, 1635 cm < ^{-1 &} gt ;.
[409] Examples 88-91
[410] The corresponding starting compounds were treated in a similar manner to give the compounds listed in Table 6 below.
[411]
[412]
[413] Examples 92-145
[414] The corresponding starting compounds were treated in a similar manner to give the compounds listed in Table 7 below.
[415]
[416]
[417]
[418]
[419]
[420]
[421]
[422] Example 146
[423] The corresponding starting compounds were treated in a similar manner to give the compounds of the formula: Foam, MS (m / z): 464 (MH ⁺ ).
[424]
[425] Example 147
[426] The corresponding starting compounds were treated in a similar manner to give compounds of the general formula, having a melting point of 140-144 [deg.] C.
[427]
[428] Example 148
[429] To a solution of (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) ) Borane bromide (300 쨉 l) was added dropwise to a solution of the compound of the general formula [ The reaction mixture was stirred at 0 占 폚 for 4 hours, to which methanol, and then a saturated aqueous solution of sodium hydrogencarbonate, was added under ice-cooling. The mixture was extracted with a mixture of ethyl acetate and tetrahydrofuran, and the organic layer was washed successively with water and brine. The mixture was dried over sodium sulfate and concentrated under reduced pressure to give light brown amorphous (227 mg). The product was suspended in chloroform and the resulting insoluble material was removed by filtration. The filtrate was subjected to silica gel column chromatography and further purified by NH-silica gel column chromatography to obtain (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (M / z): 470 (MH ⁺ ), IR (Nujol): 3279, 1632, 1593, 1569, 1518 and 1463 cm < ^{-1 &} gt ;.
[430] Example 149
[431] (1) To a solution of 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-ethoxycarbonylpyrimidine obtained in Example 1 (1) g) was treated with 10% aqueous sodium hydroxide (10 ml) at room temperature. To the reaction mixture was added dimethyl sulfoxide (5 ml), and the mixture was stirred at room temperature overnight. Citric acid was added to the resulting colorless solution until the solution became acidic. An excess of water (about 50 ml) was added to the solution, and the resulting precipitate was collected by filtration. The precipitate was washed successively with isopropyl alcohol and isopropyl ether and dried under reduced pressure to give 2-methylthio-4- (3-chloro-4-methoxybenzylamino) -5-carboxypyrimidine (1.864 g) Lt; RTI ID = 0.0 > 238-240 C < / RTI > (decomposed).
[432] (2) To a suspension of 4- (3-chloro-4-methoxybenzylamino) -5-carboxy-2-methylthiopyrimidine (200 mg) in methylene chloride (5 ml) was added oxalyl chloride And N, N-dimethylformamide were added, and the mixture was stirred at room temperature for 30 minutes and concentrated. To a suspension of the resulting acid chloride compound and 5-aminopyrimidine (84.0 mg) in methylene chloride (5 ml) was added dimethylaminopyridine (144 mg) at room temperature and the mixture was stirred at room temperature. Water was poured into the mixture , And the mixture was extracted with ethyl acetate. The extract was washed with saturated aqueous sodium hydrogen carbonate solution, water and brine, dried over sodium sulfate and concentrated. The residue was triturated with a mixture of ethyl acetate and n-hexane to give 4- (3-chloro-4-methoxybenzylamino) -5- (5- pyrimidinylaminocarbonyl) -2- (216 mg) was obtained as a light yellow needle, mp 238-240 ° C, IR (Nujol): 3251, 1666 cm ^-1 MS (m / z): 416 (M ⁺ ).
[433] (3) To a suspension of the compound obtained in the above (2) (150 mg) in chloroform (10 ml) was added m-chloroperbenzoic acid (107 mg) at 0 ° C and the mixture was stirred at 0 ° C for 1 hour And the mixture was stirred at room temperature for 1 hour. To the mixture was added m-chloroperbenzoic acid (53 mg) at 0 ° C, and the mixture was stirred at 0 ° C for 30 minutes. To the mixture was added L-propolinol (43.7 mg) and triethylamine (72.9 mg) at 0 ° C, and the mixture was stirred at room temperature for 20 hours. Water was poured into the mixture, and the mixture was extracted with chloroform. The organic layer was washed with brine, dried over sodium sulfate and concentrated under reduced pressure to give a yellow viscous oil (201 mg) which was purified by NH-silica gel flash column chromatography (solvent; ethyl acetate) and ethyl acetate and hexane (S) -4- (3-chloro-4-methoxybenzylamino) -5- (5-pyrimidinylaminocarbonyl) -2- (2-hydroxymethyl- (81 mg) was obtained as a colorless needle, mp 192-195 [deg.] C, IR (Nujol): 3279, 1669 cm- ¹ MS (m / z): 470 (MH ⁺ ).
[434] Examples 150-157
[435] The corresponding starting compounds were treated in a similar manner as in Example 149 to give the compounds listed in Table 8 below.
[436]
[437]
[438] Example 158
[439] (1) A suspension of 4- (3-chloro-4-methoxybenzylamino) -5-carboxy-2-methylthiopyrimidine (154.0 mg) obtained in Example 149 (1) Was treated with oxalyl chloride (119 L) at room temperature, and N, N-dimethylformamide was added thereto. The mixture was stirred for 1 hour and the solvent was evaporated under reduced pressure. The residue was treated with ether and left in the refrigerator overnight. The volatiles were removed under reduced pressure and the residue was treated with an excess of diazomethane at 0 < 0 > C and left overnight in the resulting jango. The reaction was quenched with methanol and the mixture was purified by silica gel chromatography (solvent: hexane: ethyl acetate = 2: 1) to give 4- (3-chloro-4-methoxybenzylamino) -5- (M / z): 327, 2115, 1607, 1567, 1461, 1377, 1357, 1141 cm- ¹ , 364 (MH ^< ⁺ & gt ^; ), melting point 162-165 DEG C (decomposition).
[440] (2) A suspension of the compound (16.5 mg) obtained in the above (1) in methanol (3 ml) was treated with toluenesulfonic acid monohydrate (16.5 mg) at room temperature. The solvent was evaporated under reduced pressure and the residue was purified by preparative TLC (solvent: hexane: ethyl acetate = 2: 1) to give 4- (3-chloro-4- methoxybenzylamino) -5- (methoxymethylcarbonyl ) -2-methylthiopyrimidine (11.0 mg) as a colorless oil.
[441] (3) A solution of the compound (11.0 mg) obtained in the above (2) in chloroform (1.0 ml) was treated with m-chloroperbenzoic acid (7.4 mg) at 0 ° C. The mixture was treated with triethylamine (8.3 L) and L-propolinol (36 mg) at room temperature and the reaction mixture was stirred overnight. The residue was purified by preparative TLC (solvent: chloroform: ethyl acetate = 1: 1) to give (S) -methanol as a colorless oil. The residue was purified by silica gel column chromatography 2- (2-hydroxymethyl-1-pyrrolidinyl) pyrimidine (8.5 mg) was obtained as a colorless oil from 4- (3-chloro-4-methoxybenzylamino) -5- (methoxymethylcarbonyl) -2- , MS (m / z): 421 (MH < ⁺ & gt ^; ).
[442] The compound (I) of the present invention and its pharmaceutically acceptable salts exhibit excellent PDE V inhibitory action, and they are pharmaceutical compounds useful for prevention or treatment such as penile erectile dysfunction.

权利要求:
Claims (26)
[1" claim-type="Currently amended] An aromatic nitrogen-containing 6-membered cyclic compound of formula (I): or a pharmaceutically acceptable salt thereof:
(I)

Wherein ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R ¹ is a substituted or unsubstituted lower alkyl group, a group of the formula: -NH-QR ³ (wherein R ³ is a substituted or unsubstituted nitrogen containing heterocyclic group, Q is a lower alkylene group or a single bond) -R ⁴ (wherein R ⁴ is a substituted or unsubstituted cycloalkyl group); R ² is a substituted or unsubstituted aryl group; One of Y and Z is a group of the formula CH CH- and the other is a group of the formula -NM.
[2" claim-type="Currently amended] The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10- (1) a lower alkyl group, (2) a hydroxy-substituted lower alkyl group, (3) a formyl group, (4) an oxo group, (5) a substituted or unsubstituted nitrogen-containing heterocyclic group, An amino group, (6) a hydroxy group, (7) a lower alkoxycarbonyl group and (8) a benzylamino group substituted by (i) a halogen atom and a lower alkoxy group, and (ii) a cycloalkylcarbamoyl group substituted with a hydroxy group group is selected from the group consisting of, R ¹ is a lower alkoxy group, a hydroxy group, a morpholinyl group, a lower alkylsulfonyl group, a di- (lower alkyl) phosphino group, a di- (lower alkyl) amino group, a pyrimidinyl-substituted lower An alkylamino group, a pyridyl group, a pyridylamino group And a group selected from the group consisting of groups piperazinyl optionally substituted lower alkyl, and optionally substituted lower alkyl group, a group of the formula -NH-QR ^3, or a group of the formula -NH-R ^4, "a substituted or unsubstituted on R ³ Containing nitrogen-containing heterocyclic group is a 5- or 6-membered nitrogen-containing complex monocyclic group or an 8- to 10-membered nitrogen-containing heterocyclic group, and the "substituted or unsubstituted nitrogen-containing heterocyclic group "substituent, a lower alkyl group, a hydroxy-substituted lower alkyl group, an oxo group, an amino group, a di-is selected from (lower alkyl) amino group, the group consisting of a lower alkanoyl group and a cyano-substituted lower alkyl group, R ⁴ is a hydroxyl group , A lower alkoxy group and a pyrimidinyloxy group, and R ² is a lower alkoxy group, a halogen atom, a cyano group, a nitro group, a hydroxy group and a lower alkyl Gt; is a phenyl group substituted with a group selected from the group consisting of < RTI ID = 0.0 >
[3" claim-type="Currently amended] The heterocyclic compound according to claim 2, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group of the formula:

Or a nitrogen-containing heterocyclic bicyclic group of the formula: wherein the 5- or 6-membered nitrogen containing complex monocyclic group is condensed with a 5- or 6-membered cyclic group,

The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a non-aromatic nitrogen-containing complex monocyclic group of the formula:

Or an aromatic nitrogen-containing heterocyclic group of the formula:
.
[4" claim-type="Currently amended] The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10- And the substituent of the "substituted or unsubstituted nitrogen containing heterocyclic group" is selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, a formyl group and an oxo group, and R ¹ is a lower alkoxy group and a morpholinyl group A group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , and the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a lower alkyl group optionally substituted by a group selected from the group consisting of R ⁴ is a cycloalkyl group substituted with a group selected from the group consisting of a hydroxyl group and a lower alkoxy group, and R ² is a lower A phenyl group substituted with a group selected from the group consisting of an alkyl group, an alkoxy group, a halogen atom and a cyano group.
[5" claim-type="Currently amended] 5. The compound according to claim 4, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group of the formula:

Or a nitrogen-containing heterocyclic bicyclic group of the formula: wherein the 5- or 6-membered non-aromatic nitrogen-containing complex monocyclic group is condensed with a 5- or 6-membered aromatic nitrogen-containing complex monocyclic group,

The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the formula:

Or an aromatic nitrogen-containing complex monocyclic group of the formula:
.
[6" claim-type="Currently amended] 2. A compound according to claim 1, wherein Ring A is a group of the formula:

R ¹ is a lower alkyl group, a lower alkoxy-substituted lower alkyl group, a morpholinyl-substituted lower alkyl group, a group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , R ³ is a group of the formula:

R ⁴ is
The Lt; / RTI >
R ² is
The Lt; / RTI >
[7" claim-type="Currently amended] The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10- And the substituent of the "substituted or unsubstituted nitrogen-containing heterocyclic group" is a group selected from the group consisting of a lower alkyl group, a hydroxy-substituted lower alkyl group, a formyl group and an oxo group, R ¹ is a lower alkoxy- , A group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , and the "substituted or unsubstituted nitrogen containing heterocyclic group" for R ³ is a 5- or 6-membered nitrogen optionally substituted by a lower alkyl group Containing heterocyclic group, R ⁴ is a hydroxy-substituted cycloalkyl group, and R ² is a phenyl group substituted with a group selected from the group consisting of a lower alkoxy group and a halogen atom.
[8" claim-type="Currently amended] 8. The compound according to claim 7, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group of the formula:

Or a group of the formula:

The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the formula:

A compound which is an aromatic nitrogen-containing complex monocyclic group of the formula:
.
[9" claim-type="Currently amended] 2. A compound according to claim 1, wherein Ring A is a group of the formula:

R ¹ is a lower alkoxy substituted lower alkyl group, a group of the formula -NH-QR ³ or a group of the formula -NH-R ⁴ , R ³ is a group of the formula:

R ⁴ is
The Lt; / RTI >
R ² is
The Lt; / RTI >
[10" claim-type="Currently amended] The compound according to claim 1, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for Ring A is a 5- or 6-membered nitrogen containing complex monocyclic group or an 8- to 10- group, wherein the substituents of the "substituted or unsubstituted nitrogen-containing heterocyclic group" is a hydroxy-substituted lower alkyl group, R ¹ contains "substituted or unsubstituted nitrogen for a group of the formula -NH-QR ^3, R ³ Heterocyclic group "is a 5- or 6-membered nitrogen-containing complex monocyclic group optionally substituted by a lower alkyl group, and R ² is a phenyl group substituted by a group selected from the group consisting of a lower alkoxy group and a halogen atom.
[11" claim-type="Currently amended] 11. The compound according to claim 10, wherein the nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for ring A is a 5- or 6-membered nonaromatic nitrogen containing complex monocyclic group of the formula:

Or a group of the formula:

The nitrogen-containing heterocyclic group of the "substituted or unsubstituted nitrogen-containing heterocyclic group" for R ³ is a nonaromatic nitrogen-containing complex monocyclic group of the following formula:

Or an aromatic nitrogen-containing complex monocyclic group of the formula:
.
[12" claim-type="Currently amended] 2. A compound according to claim 1, wherein Ring A is a group of the formula:

R ¹ is a group of the formula -NH-QR ³ , R ³ is a group of the formula:

R ² is
The Lt; / RTI >
[13" claim-type="Currently amended] 13. Compounds according to any one of claims 1 to 12, wherein Y is a group of the formula N-M < 1 > and Z is a group of the formula CH-.
[14" claim-type="Currently amended] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
4- (3-cyano-4-methoxybenzylamino) -5- [N- ( 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- Trans-4-methoxycyclohexyl) carbamoyl] pyrimidine;
4- (3-cyano-4-methoxybenzylamino) -5- [N- ( Trans-4-hydroxycyclohexyl) carbamoyl] pyrimidine;
4- (3-cyano-4-methoxybenzylamino) -5- [N- ( 2-morpholinoethyl) carbamoyl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (2-morpholinoethyl) carbazole Yl] pyrimidine;
(2S) -2-hydroxymethyl-1-pyrrolidinyl] -4- (3-chloro-4-methoxybenzylamino) 2-morpholinyl] methyl] carbamoyl] -pyrimidine;
[(2S) -2-hydroxymethyl-1-pyrrolidinyl] -4- (3-chloro-4- methoxybenzylamino) 2-morpholinyl] methyl] carbamoyl] -pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyrimidinylmethyl) Yl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4-hydroxycyclohexyl) carbazole Yl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4- hydroxycyclohexyl) carbamoyl] pyrimidine Midin;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- Trans-4-hydroxycyclohexyl) carbamoyl] pyrimidine;
(3-chloro-4-methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) ) ≪ / RTI > carbamoyl] pyrimidine;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-morpholinoethyl) carbamoyl] pyrimidine;
4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4-methoxybenzylamino) -5-acetylpyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyridazinylmethyl) Yl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyridylmethyl) carbamoyl ] Pyrimidine;
(3-chloro-4-methoxybenzylamino) -5- [2-hydroxymethyl-1-pyrrolyl Dinyl] pyrazine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2-morpholinoethyl) carbonyl] Midin;
4- (3-Chloro-4-methoxybenzylamino) -5- [N- [2-fluoro- (4-methyl-2-morpholinyl) methyl] carbamoyl] pyrimidine;
3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
2- [N- (2-pyrimidinylmethyl) carbamoyl] -3- (3-chloro-4- methoxybenzylamino) -5- (5,6,7,8-tetrahydroimidazo [ , 2-a] pyrazin-7-yl) pyrazine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2- methoxyethyl) carbonyl] pyrimidine ;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[15" claim-type="Currently amended] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (4-pyrimidinylmethyl) Yl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4-hydroxycyclohexyl) carbazole Yl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (trans-4- hydroxycyclohexyl) carbamoyl] pyrimidine Midin;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-morpholinoethyl) carbamoyl] pyrimidine;
4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine;
(3-chloro-4-methoxybenzylamino) -5- [2-hydroxymethyl-1-pyrrolyl Dinyl] pyrazine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5 - [(2- methoxyethyl) carbonyl] pyrimidine ;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[16" claim-type="Currently amended] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine;
4- (3-chloro-4-methoxybenzylamino) -5- [N- (2-morpholinoethyl) carbazole Yl] pyrimidine;
2- (5,6,7,8-Tetrahydroimidazo [1,2-a] pyrazin-7-yl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- 2-pyrimidinylmethyl) carbamoyl] pyrimidine;
4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) Polynoethyl) carbamoyl] pyrimidine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (5-pyrimidinylmethyl) Yl] pyrimidine
(3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
3- (3-chloro-4-methoxybenzylamino) -5- (2-hydroxymethyl-1-pyrrolyl) Dinyl) pyrazine;
(S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[17" claim-type="Currently amended] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [N- (2-pyrimidinylmethyl) Yl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[18" claim-type="Currently amended] 4- (3-Chloro-4-methoxybenzylamino) -5- [N- (2-morpholin-4-yl) ≪ / RTI > or a pharmaceutically acceptable salt thereof.
[19" claim-type="Currently amended] (S) -2- (2-hydroxymethyl-1-pyrrolidinyl) -4- (3-chloro-4- methoxybenzylamino) -5- [ / RTI > pyrazolyl) carbamoyl] pyrimidine, or a pharmaceutically acceptable salt thereof.
[20" claim-type="Currently amended] 19. A pharmaceutical composition comprising the compound described in any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof as an active ingredient.
[21" claim-type="Currently amended] 20. A method of treating penile erectile dysfunction comprising administering to a patient in need thereof an effective amount of a compound as set forth in any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.
[22" claim-type="Currently amended] 20. A method of treating pulmonary hypertension comprising administering to a patient in need thereof an effective amount of a compound described in any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.
[23" claim-type="Currently amended] 20. A method of treating diabetic gastroparesis comprising administering to a patient in need thereof an effective amount of a compound as set forth in any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof.
[24" claim-type="Currently amended] 19. The use of a compound as claimed in any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for the treatment of a patient suffering from a penile erectile dysfunction.
[25" claim-type="Currently amended] 20. The use of a compound as claimed in any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for the treatment of diabetic gastroparesis patients.
[26" claim-type="Currently amended] 19. The use of a compound as claimed in any one of claims 1 to 19, or a pharmaceutically acceptable salt thereof, for the treatment of pulmonary hypertension patients.

类似技术:

---

公开号 | 公开日 | 专利标题

---

JP5789288B2|2015-10-07|soluble guanylate cyclase activator

---

JP5820882B2|2015-11-24|Quinolines and quinoxaline derivatives as kinase inhibitors

---

AU2009322836B2|2013-04-04|Soluble guanylate cyclase activators

---

US8563730B2|2013-10-22|Pyrazole and fused pyrazole glucokinase activators

---

CA2564201C|2011-01-18|Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands

---

AU730670B2|2001-03-08|Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase | for the treatment of sexual dysfunction

---

CN102079743B|2020-08-25|Dipeptidyl peptidase inhibitors

---

DE60315516T2|2008-04-17|Pyridazinone derivatives as cdk2 inhibitors

---

US7572914B2|2009-08-11|Kinase inhibitors

---

US7388019B2|2008-06-17|3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes

---

JP5227032B2|2013-07-03|Pyrrolopyrimidines useful as inhibitors of protein kinases

---

JP2862374B2|1999-03-03|Pyrazoles and pyrazolopyrimidines having CRF antagonist activity

---

EP2549875B1|2015-05-13|Soluble guanylate cyclase activators

---

KR100854050B1|2008-08-26|Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors

---

ES2243037T3|2005-11-16|Inhibitors of the pde 5 of gmpc pirazolopirimidinone for the treatment of sexual dysfunction.

---

JP5069678B2|2012-11-07|Aminocyclohexane as a dipeptidyl peptidase IV inhibitor for the treatment or prevention of diabetes

---

US7687625B2|2010-03-30|Dipeptidyl peptidase inhibitors

---

US9783552B2|2017-10-10|Soluble guanylate cyclase activators

---

ES2351622T3|2011-02-08|5,7-diaminopirazolo [4,3-d] pyrimidins with inhibiting activity of the pde-5.

---

US5866573A|1999-02-02|Pyrazinone thrombin inhibitors

---

US6174884B1|2001-01-16|1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives

---

RU2269529C2|2006-02-10|Derivatives of quinoline xanthine and 8-isoquinoline xanthine as inhibitors of phosphodiesterase pde-5

---

EP0656898B1|1997-01-22|Pyridopyrimidinone antianginal agents

---

JP4797021B2|2011-10-19|Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes

---

EP2499126B1|2015-01-07|Fused bicyclic pyridine and pyrazine derivatives as kinase inhibitors

同族专利:

---

公开号 | 公开日

---

WO2001019802A1|2001-03-22|

---

BE2013C051I2|2019-10-16|

---

NO20021308L|2002-04-24|

---

DK1219609T3|2007-05-21|

---

TWI258471B|2006-07-21|

---

US20030229095A1|2003-12-11|

---

EP1219609A1|2002-07-03|

---

RU2233273C2|2004-07-27|

---

BR0014526A|2002-06-18|

---

AU7311800A|2001-04-17|

---

US6656935B2|2003-12-02|

---

CN102584799A|2012-07-18|

---

US20030032647A1|2003-02-13|

---

IL148291A|2006-10-05|

---

DE60034239T2|2007-12-27|

---

AT358670T|2007-04-15|

---

CN1374953A|2002-10-16|

---

ES2283315T3|2007-11-01|

---

BG106566A|2003-02-28|

---

HU0202795A3|2003-03-28|

---

DE60034239D1|2007-05-16|

---

NO2013018I1|2014-06-02|

---

LU92249I9|2019-01-03|

---

AR025668A1|2002-12-11|

---

BG65453B1|2008-08-29|

---

HK1044535A1|2007-06-29|

---

NO2013018I2|2015-01-12|

---

PT1219609E|2007-06-19|

---

NO322038B1|2006-08-07|

---

LU92249I2|2013-09-10|

---

TR200200701T2|2002-06-21|

---

RU2233273C3|2019-07-17|

---

BR0014526B1|2013-09-10|

---

IL148291D0|2002-09-12|

---

NO20021308D0|2002-03-15|

---

HU0202795A2|2003-02-28|

---

BRPI0014526B8|2017-03-21|

---

EP1219609B1|2007-04-04|

---

CA2383466C|2009-08-25|

---

US6797709B2|2004-09-28|

---

EP1219609A4|2002-11-06|

---

HU225917B1|2007-12-28|

---

CA2383466A1|2001-03-22|

---

KR100532546B1|2005-12-01|

---

AU767558B2|2003-11-13|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1999-09-16|Priority to JPJP-P-1999-00261852

---

1999-09-16|Priority to JP26185299

---

2000-04-28|Priority to JPJP-P-2000-00130371

---

2000-04-28|Priority to JP2000130371

---

2000-09-13|Application filed by 찌바따 이찌로, 다나까 도시오, 다나베 세이야꾸 가부시키가이샤

---

2002-06-21|Publication of KR20020047170A

---

2005-12-01|Application granted

---

2005-12-01|Publication of KR100532546B1

---

2016-07-27|First worldwide family litigation filed

优先权:

---

申请号 | 申请日 | 专利标题

---

JPJP-P-1999-00261852|1999-09-16|

---

JP26185299|1999-09-16|

---

JPJP-P-2000-00130371|2000-04-28|

---

JP2000130371|2000-04-28|